Biorestorative Therapies vs Cervomed
Cervomed is the larger business, with $4.0m of revenue in fiscal 2025 against $359,700 for Biorestorative Therapies (11.1 times as much). Biorestorative Therapies grew faster (-10.3% against -58.9%). Cervomed kept more of each dollar of sales as profit: a net margin of -673.1% against -3959.4%.
| Latest fiscal year | Biorestorative TherapiesBRTX, 2025 | CervomedCRVO, 2025 |
|---|---|---|
| Revenue | $359,700 | $4.0m |
| Revenue growth | -10.3% | -58.9% |
| Net income | −$14.2m | −$27.0m |
| Operating margin | — | -706.2% |
| Net margin | -3959.4% | -673.1% |
| Return on equity | — | -93.9% |
| Free cash flow | −$10.9m | −$23.4m |
| Cash | $1.5m | $8.2m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $0 | — |
| Employees | 14 | 15 |
| Market value | $36.4m | $21.0m |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 19 buys, 0 sales |